Physician profile
Lisa S Matson
NPI 1083683569
$2,569.75
in general payments reported to CMS, 2019-2025
34 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.21 · 2020: $264 · 2021: $529 · 2022: $473 · 2023: $439 · 2024: $419 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $722.88 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $488.34 | 2019-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $211.36 | 2023-2025 | Auvelity |
| Allergan, INC. | $179.57 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.49 | 2020-2024 | Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $87.09 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $81.99 | 2022-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $78.22 | 2020-2024 | Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $76.89 | 2024-2025 | Fanapt |
| Organogenesis INC. | $45.19 | 2025 | Via Matrix |
| Horizon Therapeutics Plc | $45.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $37.19 | 2024-2025 | Gvoke Hypopen |
| Pfizer INC. | $32.17 | 2024 | |
| Dexcom, INC. | $31.16 | 2021-2023 | Dexcom G6 Transmitter |
| Globus Medical, INC. | $25.23 | 2025 | Senza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.39 | 2025 | |
| Astellas Pharma US INC | $24.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $23.10 | 2023 | Shingrix, Arexvy |
| Genentech USA, INC. | $22.28 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.86 | 2021 | |
| Lundbeck LLC | $19.94 | 2024 | Rexulti |
| Exact Sciences Corporation | $19.88 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $18.16 | 2023 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $17.84 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $17.23 | 2021 | |
| Valinor Pharma, LLC | $16.95 | 2025 | Movantik |
| Avanir Pharmaceuticals, INC. | $16.66 | 2020 | |
| Almatica Pharma LLC | $16.45 | 2025 | Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.90 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.25 | 2025 | Nuzyra |
| Eisai INC. | $14.41 | 2020 | |
| Phathom Pharmaceuticals, INC. | $12.31 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $11.57 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Matson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.